Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019-Reference-Cited by-同舟云学术

Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019

Published:2020-11 Issue:4 Volume:17 Page:696-701
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Knopman David S.¹,Jones David T.¹²,Greicius Michael D.³

Affiliation:

1. Department of Neurology, Mayo Clinic Rochester Minnesota USA

2. Department of Radiology Mayo Clinic Rochester Minnesota USA

3. Department of Neurology and Neurological Sciences Stanford University School of Medicine Stanford California USA

Funder

National Science Foundation

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12213

Reference12 articles.

1. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

2. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

3. EMERGE and EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer's Disease (https://investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-3b557697c06f).2019.

4. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

5. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Cited by 377 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical Trials;2024-09-04

2. Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease;Frontiers in Cellular Neuroscience;2024-09-02

3. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD);Bioorganic & Medicinal Chemistry;2024-09

4. Alzheimer’s disease and immunotherapy;Current Medicine;2024-08-23

5. How Attribution Theory Helps to Explain Psychiatric Nosology;American Journal of Health Research;2024-08-20